Latest & greatest articles for bronchiolitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on bronchiolitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on bronchiolitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Bronchiolitis

Bronchiolitis is mainly caused by the respiratory syncytial virus (RSV). The virus travels down to the bronchioles in the lungs causing them to become inflamed making it difficult to breath.

Almost every child will be infected with RSV by the time they reach two years. Adults can also contract the virus, typically during winter months.

In mild cases bronchiolitis will clear up without treatment. The virus that causes bronchiolitis travels through tiny droplets of liquid and can be passed through the air or contracted by touching infected surfaces.

Symptoms include: Sore throat, dry cough, blocked nose and aches and pains throughout the body.

Although there is no cure for chronic bronchiolitis research and clinical studies on bronchiolitis suggest that some lifestyle changes can ease symptoms: avoid smoking, eat a healthy diet and maintain regular exercise. In extreme cases steroids can be prescribed to help minimise inflammation.

Read more on medications used to treat bronchiolitis and the causes of the virus.

Top results for bronchiolitis

81. Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis

Steroids and bronchodilators for acute bronchiolitis in the first two years of life: systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

82. Nebulized Hypertonic Saline for Bronchiolitis

Nebulized Hypertonic Saline for Bronchiolitis Nebulized Hypertonic Saline for Bronchiolitis – TheNNTTheNNT Nebulized Hypertonic Saline for Bronchiolitis in Infants 1 less hospital day IMPORTANT! In Summary, for those who received the nebulized hypertonic saline: Benefits in NNT Hospitalized infants were helped by a 1-day decrease in their hospital stay Harms in NNT None were harmed View As: NNT % Source: Efficacy Endpoints: Duration of Hospital Stay, Decrease in Clinical Severity Scores (...) , Decrease in Admission Rates Harm Endpoints: Tachycardia, Hypertension, Pallor, Tremor, Nausea, and Vomiting Narrative: Acute bronchiolitis is the one of the most common respiratory infections in infants. It affects the lower respiratory tract and is usually caused by a virus, with respiratory syncytial virus (RSV) being the most common pathogen. It is estimated that nearly all infants are infected with RSV and that between 1 and 2% of these develop symptoms severe enough to warrant admission. While

2011 theNNT

83. WITHDRAWN: Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing. (Abstract)

WITHDRAWN: Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing. Acute bronchiolitis in infants and young children is associated with long-term airway disease also known as post-bronchiolitic wheezing. Two major hypotheses have been proposed to explain the association between bronchiolitis and PBW. The first hypothesis considers bronchiolitis to be the first manifestation of recurrent wheezing in infants and children who are susceptible (...) to obstructive airway disease. The second hypothesis suggests that the infection and concomitant inflammatory reaction in the acute phase leads to airway epithelium injury resulting in long-term obstructive airway disease. In line with the latter hypothesis, corticosteroids may have a beneficial effect on the prevention of post-bronchiolitic wheezing.The objective of this review was to evaluate the effect of inhaled corticosteroids, started during the acute phase of bronchiolitis, on the prevention of post

2011 Cochrane

84. Steam inhalation or humidified oxygen for acute bronchiolitis in children up to three years of age. (Abstract)

Steam inhalation or humidified oxygen for acute bronchiolitis in children up to three years of age. Acute bronchiolitis is a common respiratory infection and a major cause of morbidity in young children. It is treated with bronchodilators (for example, salbutamol), corticosteroids or humidified air (steam inhalation or cool mist). Steam inhalation is preferred in low-income countries as it is inexpensive and easily available. It is thought to act as a secretolytic agent to lighten secretions (...) (1981 to March 2010), AMED (1985 to March 2010), Web of Science (2000 to March 2010) and LILACS (1982 to March 2010).Randomised controlled trials involving children up to three years old with bronchiolitis comparing steam inhalation (or cool mist) or humidified oxygen against bronchodilators, corticosteroids or placebo; alone or in combination.Two review authors independently assessed trial quality and extracted data.Only one study (156 children aged between seven weeks and 24 months with signs

2011 Cochrane

85. Randomised controlled trial: Repeated dosing of nebulised 5% saline improves respiratory scores in inpatients with mild to moderate bronchiolitis at 48 h

Randomised controlled trial: Repeated dosing of nebulised 5% saline improves respiratory scores in inpatients with mild to moderate bronchiolitis at 48 h Repeated dosing of nebulised 5% saline improves respiratory scores in inpatients with mild to moderate bronchiolitis at 48 h | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use (...) bronchiolitis at 48 h Article Text Therapeutics Randomised controlled trial Repeated dosing of nebulised 5% saline improves respiratory scores in inpatients with mild to moderate bronchiolitis at 48 h Shawn Ralston Statistics from Altmetric.com Commentary on: Al-Ansari K , Sakran M , Davidson BL , et al . Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants. . Context Nebulised hypertonic saline for acute viral bronchiolitis was first brought to public scrutiny in 2002

2011 Evidence-Based Medicine

86. Palivizumab for immunoprophylaxis of respiratory syncitial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses

Palivizumab for immunoprophylaxis of respiratory syncitial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk (...) infants and young children: a systematic review and additional economic modelling of subgroup analyses Wang D, Bayliss S, Meads C Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic

2011 Health Technology Assessment (HTA) Database.

87. Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants (Abstract)

Nebulized 5% or 3% hypertonic or 0.9% saline for treating acute bronchiolitis in infants To compare the efficacy and safety of 5%, 3%, and 0.9% saline solution for treating acute bronchiolitis in the prehospital setting.This was a double-blind trial including consecutive infants aged <18 months treated in an urban urgent care setting. A total of 165 patients were randomized to receive nebulized 5%, 3%, or 0.9% (normal) saline with epinephrine every 4 hours. The primary efficacy outcome (...) was bronchiolitis severity score improvement at 48 hours (chi2 analysis). Scores and oxygen saturation immediately before and after each treatment were recorded to assess safety.A total of 187 previously healthy infants (median age, 3.1 months) diagnosed with bronchiolitis were enrolled. Positivity for respiratory syncytial virus was similar in the 3 treatment groups (mean, 56%). At 48 hours, the mean severity score for the 5% saline group was 3.69+/-1.09, and that for the 0.9% saline group was 4.12+/-1.11 (P

2010 EvidenceUpdates Controlled trial quality: predicted high

88. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients Full Text available with Trip Pro

Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients Despite the importance of bronchiolitis obliterans syndrome (BOS) in lung transplantation, little is known regarding the factors that influence survival after the onset of this condition, particularly among bilateral transplant recipients.To identify factors that influence survival after the onset of BOS among bilateral lung transplant recipients.The effect of demographic or clinical factors, occurring

2010 EvidenceUpdates

89. WITHDRAWN: Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Full Text available with Trip Pro

WITHDRAWN: Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Acute bronchitis leading to ongoing exacerbations is a serious condition predisposed to by viruses, bacteria or environmental factors. It can be fatal. Antibiotic therapy is not particularly useful. An oral Haemophilus influenzae vaccine has been developed.To assess the effects of an oral, monobacterial whole-cell, killed, nontypeable H. influenzae vaccine in protecting (...) against recurrent acute episodes in chronic bronchitis.In this updated review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006), MEDLINE (1966 to January Week 4 2006), EMBASE (1990 to September 2005) and ISI Current Contents (2004 to May 2006).Randomised controlled trials (RCTs) comparing the effects of the H. influenzae vaccine on patients with recurrent acute exacerbations of chronic bronchitis were included when there was overt matching

2010 Cochrane

90. High Flow Nasal Cannulae Therapy in Infants with Bronchiolitis

High Flow Nasal Cannulae Therapy in Infants with Bronchiolitis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2010 PedsCCM Evidence-Based Journal Club

91. Review: pneumococcal vaccination does not prevent pneumonia, bacteraemia, bronchitis, or mortality

Review: pneumococcal vaccination does not prevent pneumonia, bacteraemia, bronchitis, or mortality Review: pneumococcal vaccination does not prevent pneumonia, bacteraemia, bronchitis, or mortalityCommentary | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: pneumococcal vaccination does not prevent pneumonia, bacteraemia, bronchitis, or mortalityCommentary Article Text Treatment Review: pneumococcal vaccination does not prevent

2010 Evidence-Based Nursing

92. Epinephrine and dexamethasone in children with bronchiolitis

Epinephrine and dexamethasone in children with bronchiolitis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2010 PedsCCM Evidence-Based Journal Club

93. A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department Full Text available with Trip Pro

A randomized trial of nebulized 3% hypertonic saline with epinephrine in the treatment of acute bronchiolitis in the emergency department To determine whether nebulized 3% hypertonic saline with epinephrine is more effective than nebulized 0.9% saline with epinephrine in the treatment of bronchiolitis in the emergency department.Randomized, double-blind, controlled trial.Single-center urban pediatric emergency department.Infants younger than 12 months with mild to moderate (...) baseline characteristics. The RACS from baseline to 120 minutes demonstrated no improvement in respiratory distress in the hypertonic saline group compared with the normal saline control group. The change in oxygen saturation in the hypertonic saline group was not significant when compared with the control group. Rates of admission and return to the emergency department were not different between the 2 groups.In the treatment of acute bronchiolitis, hypertonic saline and epinephrine did not improve

2010 EvidenceUpdates Controlled trial quality: predicted high

94. Pharmacologic Treatment of Bronchiolitis in Infants and Children: A Systematic Review

Pharmacologic Treatment of Bronchiolitis in Infants and Children: A Systematic Review PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2010 PedsCCM Evidence-Based Journal Club

95. WITHDRAWN. Surfactant therapy for bronchiolitis in critically ill infants. (Abstract)

WITHDRAWN. Surfactant therapy for bronchiolitis in critically ill infants. Viral bronchiolitis is a common cause of respiratory failure in infants and children, and accounts for a significant portion of intensive care unit (ICU) admissions during seasonal epidemics. Currently there is no evidence to support the use of anything but supportive care for this disease. Surfactant is a potentially promising therapy; alterations in its composition have been described in bronchiolitis, and it may play (...) a role in the host immunity for this disease.To assess the efficacy of exogenous surfactant for the treatment of bronchiolitis in mechanically ventilated infants and children.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, 2006, issue 1) which contains the Acute Respiratory Infections Group's Specialized Register; MEDLINE (1966 to Week 1, February 2006); and EMBASE (1990 to September 2005).Randomised controlled trials (RCTs) comparing surfactant

2010 Cochrane

96. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data

The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

97. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. (Abstract)

Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. With improvements in supportive care, both long-term survival following allogeneic hematopoietic stem cell transplantations (HSCTs) and the indications for this procedure have increased. As a result, the number of patients living with long-term toxic effects due to HSCT has increased. A once rare condition of the donor immune cells attacking healthy host tissues, termed chronic graft-vs-host disease, has become (...) a more common phenomenon. When chronic graft-vs-host disease affects the lung tissue, bronchiolitis obliterans syndrome ensues. Recent data suggest that bronchiolitis obliterans syndrome may affect up to 6% of HSCT recipients and dramatically alters survival, with overall survival of only 13% at 5 years. These statistics have not improved since the first presentation of this disease over 20 years ago. Challenges to the progress of medical management of bronchiolitis obliterans syndrome include

2009 JAMA

98. Nebulised hypertonic saline significantly decreases length of hospital stay and reduces symptoms in children with bronchiolitis

Nebulised hypertonic saline significantly decreases length of hospital stay and reduces symptoms in children with bronchiolitis BestBets: Nebulised hypertonic saline significantly decreases length of hospital stay and reduces symptoms in children with bronchiolitis Nebulised hypertonic saline significantly decreases length of hospital stay and reduces symptoms in children with bronchiolitis Report By: Daniel Horner - ST3 Emergency Medicine / Critical Care Search checked by Rachel Jenner (...) - Paediatric Emergency Medicine Consultant Institution: Booth Hall Childrens Hospital Date Submitted: 31st January 2007 Date Completed: 3rd July 2009 Last Modified: 3rd July 2009 Status: Green (complete) Three Part Question In [children Clinical Scenario A 3 month old books in to the Emergency Department with a 4 day history of a coryzal illness followed by breathing difficulties and decreased oral intake. It is December. Inwardly you sigh heavily, berating the fact that bronchiolitis season is upon you

2009 BestBETS

99. Is continuous positive airway pressure effective in bronchiolitis?

Is continuous positive airway pressure effective in bronchiolitis? BestBets: Is continuous positive airway pressure effective in bronchiolitis? Is continuous positive airway pressure effective in bronchiolitis? Report By: V Palanivel, M A Anjay - Paediatric Registrars Institution: Addenbrooke's Hospital, Cambridge and James Paget University Hospitals NHS Foundation Trust, Gorleston, Great Yarmouth Date Submitted: 27th February 2004 Date Completed: 5th May 2009 Last Modified: 5th May 2009 Status (...) : Green (complete) Three Part Question In [infants with worsening bronchiolitis] does [nasal continuous positive airway pressure compared with the standard management of oxygen and supportive care] improve [clinical status and/or avoid mechanical ventilation]? Clinical Scenario A 3-month-old boy is admitted to the paediatric ward with bronchiolitis. He is initially managed with oxygen, nursing care and intravenous fluids. However, his respiratory distress worsens a few hours after admission

2009 BestBETS

100. Review: pneumococcal vaccination is not effective for preventing pneumonia, bacteraemia, bronchitis, or mortality

Review: pneumococcal vaccination is not effective for preventing pneumonia, bacteraemia, bronchitis, or mortality Review: pneumococcal vaccination is not effective for preventing pneumonia, bacteraemia, bronchitis, or mortalityReview: pneumococcal vaccination is not effective for preventing pneumonia, bacteraemia, bronchitis, or mortality | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via (...) for preventing pneumonia, bacteraemia, bronchitis, or mortalityReview: pneumococcal vaccination is not effective for preventing pneumonia, bacteraemia, bronchitis, or mortality Article Text Therapeutics Review: pneumococcal vaccination is not effective for preventing pneumonia, bacteraemia, bronchitis, or mortality Review: pneumococcal vaccination is not effective for preventing pneumonia, bacteraemia, bronchitis, or mortality Statistics from Altmetric.com QUESTION Is pneumococcal vaccination effective

2009 Evidence-Based Medicine